EP Patent

EP1841867A1 — COMPLEX CONTAINING SiRNA, ShRNA OR ANTISENSE MOLECULE AND FUNCTIONAL ENTITY, FOR IMPROVED SPECIFICITY AND DELIVERY

Assigned to Avaris AB · Expires 2007-10-10 · 19y expired

What this patent protects

The present invention relates to modification of nucleic acids for specific delivery in vitro and in vivo. More specifically, the present invention relates to modification of RNA or DNA molecules in order to add functions in terms of delivery and specificity to RNA interference o…

USPTO Abstract

The present invention relates to modification of nucleic acids for specific delivery in vitro and in vivo. More specifically, the present invention relates to modification of RNA or DNA molecules in order to add functions in terms of delivery and specificity to RNA interference or antisense technology. A specific binding domain is incorporated into the nucleic acid to which a complementary nucleic acid, conjugated to a biologically active molecule, can hybridize.

Drugs covered by this patent

Patent Metadata

Patent number
EP1841867A1
Jurisdiction
EP
Classification
—
Expires
2007-10-10
Drug substance claim
No
Drug product claim
No
Assignee
Avaris AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.